TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06512090: EMPOWER-ET: Phase 3 Double-Blind Trial of Ulixacaltamide (PRAX-944) in Essential Tremor

Sponsor: Praxis Precision Medicines, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 260 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,980,048

Rescue Site Savings

+$1,320,032

Unlock Full NCT06512090 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06512090 Rescue Dossier →